BERTILIMUMAB

BERTILIMUMAB

Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

March 27, 2017

What’s Next for Immune Pharma? Pure-Play Spin-Off Companies | Read more 

 

PRESS RELEASE March 13, 2017

Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement | Read more 

 

EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. | Read more 

 

See All News 

Upcoming Events

No upcoming events found

See All Events